Dublin, Aug. 10, 2018 (GLOBE NEWSWIRE) -- The "Human Microbiome: The Unavoidable Companion Technological Report and Market Scenario" report has been added to ResearchAndMarkets.com's offering.

The global human microbiome market is nearly expected to grow by $521.23 million in 2022.

This report provides an in-depth diverse perspective and the importance of human microbiome in health and disease-related conditions. Alterations in human microbiome occur by exposure to various extrinsic factors like diet, xenobiotics, drugs as well as pathogens which contribute to the pathogenesis of various metabolic, neurological, immunological, and cancer-promoting diseases. It will also disclose the key aspects of the human microbiome as well as the current biotechnological tools and techniques for studying the human microbiome.

Various human microbial studies are known to identify and categorize the bacterial taxa and functions that are shared by a majority of individuals. This report will cover the factors which can affect the human microbiome as well as various studies which are well known and can be used as a tool for identifying the potential of the functional microbiome. It will also emphasize on the various microbiome-based markers which can be useful in determining the disease or the risk of disease and various approaches like Fecal Microbiota Transplant (FMT), Genetically engineered probiotics, etc. which have a profound effect in improving the microbiome condition.

This report covers its market trends analysis and its growth in the commercial market. It will also include the major key players like Agilent technologies, Abbott, Biocartis, etc. which are actively working in this field and will also be discussed its future market scenario.

This report will also focus on global market competitive analysis as well as the Major competitors/players in this market which are actively working on the human microbiome. It will also discuss the agreements, partnerships, collaborations/ Joint Ventures, acquisitions/mergers, new products launch, other key strategies in this field.

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 Introduction

4 Human Microbiome: Overview
4.1 Primitive Companion
4.1.1 Microbiome Diversity
4.1.2 Microbiome Commensal or Symbiosis
4.1.3 Microbiome as a Human Organ
4.2. The Common Core Microbiome in Human Large Intestine
4.2.1 Phylogenetic Core
4.2.2 Minimal Intestinal Metagenome
4.3 Host Biology and Dysbiosis
4.4 The Role of The Microbiome in Human Health and Disease
4.4.1 The Microbiome and Human Health
4.4.2 The Pediatric Microbiome
4.4.3 Innate Immune Response
4.4.4 Role of Microbiome in Diseases
4.5 Microbiome as a Multipurpose Biomarker
4.6 Microbiome Cross-Talk
4.6.1 Microbiome-Microbiome Cross Talk
4.6.2 Host-Microbiome Cross Talk
4.7 The Human Microbiome Projects
4.8 Current Methods for Studying the Human Microbiome
4.9 Microbiome: Timeline
4.10 Latest Research and Reviews

5 Research Scope

6 Research Methodology

7 Research Approach

8 Research Sources

9 Technical Analysis
9.1 Human Microbiome in IVD And Other Healthcare Applications
9.1.1 Microbiome - Bacteria in Disease Processes
9.1.2 Growing Interest in the Microbiome
9.1.3 Metagenomics
9.1.4 Metabolomic Profiling
9.1.5 Microbiome Diagnostics
9.1.6 Selected Molecular Microbiome-Based Tests
9.1.7 Diagnostic Biomarkers
9.1.8 Precision or Personalized Medicine Approaches
9.1.9 Fecal Microbiome Transplantation (FMT)
9.1.10 Other Selected Microbiome-Related Therapeutic Approaches
9.1.11 Microbiome Modulators
9.2 Human Microbiome in Disease
9.2.1 Human Microbiome and Infectious Diseases
9.2.1.1 Clostridium Difficile Infection
9.2.1.2 Helicobacter Pylori Infection
9.2.1.3 Bacterial Vaginosis
9.2.1.4 HIV Infection
9.2.1.5 Fungal Infection
9.2.2 Human Microbiome and Liver Diseases
9.2.3 Human Microbiota Associated with Gastrointestinal Malignancy
9.2.3.1 Gastric Cancer
9.2.3.2 Colorectal Cancer
9.2.3.3 Esophageal Cancer
9.2.4 Human Microbiome and Metabolic Disorders
9.2.4.1 Obesity
9.2.4.2 Type 2 Diabetes
9.2.5 Human Microbiome and Autoimmune Disorder
9.2.5.1 Celiac Disease
9.2.5.2 Rheumatoid Arthritis
9.2.5.3 Ankylosing Spondylitis
9.2.5.4 Psoriatic Arthritis
9.2.5.5 Systemic Lupus Erythematosus
9.2.5.6 Sjogren's Syndrome
9.2.5.7 Vasculitis
9.2.6 Human Microbiome and Other Diseases
9.2.6.1 Allergic Diseases
9.2.6.2 Psychiatric Diseases
9.2.6.3 Atherosclerosis
9.2.6.4 Paneth Cell Dysfunction
9.2.6.5 Cerebrovascular Disease
9.2.6.6 Multiple Sclerosis
9.3 Advancements in Human Microbiome Technology
9.4 Ingredients Effecting Human Microbiome
9.4.1 Proteins
9.4.2 Lipids
9.4.3 Carbohydrates
9.4.4 Glutens
9.4.5 Polyphenols
9.4.6 Green Vegetables
9.4.7 Fruits
9.4.8 Dairy products
9.4.9 Meat
9.4.10 Junk Foods
9.4.11 Fermented Foods
9.4.12 Processed Foods
9.4.13 Antibiotics
9.4.14 Probiotics
9.4.15 Prebiotics
9.4.16 Other Active agents

10 Mode of Administration of Microbiome Products

11 Microbiome Product forms

12 Market Analysis
12.1 Market Overview
12.2 Human Microbiome Market Segmentation
12.2.1 Based on Application
12.2.1.1 Therapeutic
12.2.1.2 Diagnostic
12.2.2 Based on Disease Type
12.2.3 Based on Product Type
12.2.3.1 Prebiotics
12.2.3.2 Foods
12.2.3.3 Drugs
12.2.3.4 Diagnostic Devices
12.2.3.5 Nutritionally Incomplete Formulae
12.2.3.6 Formulae for Metabolic Disorders
2.2.3.7 Nutritionally Complete Formulae
12.2.3.8 Oral Rehydration Products
12.2.3.9 Other Probiotics Supplements
12.2.4 Based on Distribution Channel
12.2.5 Based on End Users
12.2.6 Based on Geography
12.3 Global Human Microbiome Market Competitive Analysis
12.4 Human Microbiome Market Major Market Competitors/Players

13 Market Trend Analysis
13.1 Drivers
13.2 Restraints
13.3 Opportunities
13.4 Threats
13.5 Application Analysis
13.6 Product Analysis
13.7 Research Scenario
13.8 Emerging Markets
13.9 Supply Chain Analysis
13.10 Futuristic Market Scenario
13.11 Burning Issues

14 Key Microbiome Players (Company Profiling)
14.1 4D Pharma plc
14.2 Abbott Diagnostics
14.3 Agilent Technologies Inc.
14.4 Anaeropharma Science
14.5 AOBiome, LLC
14.6 Aperiomics, Inc.
14.7 Atlas Biomed
14.8 AvidBiotics
14.9 Beckman Coulter/Danaher
14.10 Becton, Dickinson and Company (BD)
14.11 Biocartis Group
14.12 C3J Therapeutics (formerly C3 Jian)
14.13 Crestovo (Finch Therapeutics Group)
14.14 Danaher Corporation
14.15 Eppendorf AG
14.16 Evelo Biosciences
14.17 Evolve Biosystems
14.18 Finch Therapeutics Group
14.19 One Codex
14.20 OpenBiome
14.21 Optibiotix
14.22 OraSure Technologies, Inc.
14.23 Osel, Inc.
14.24 PerkinElmer, Inc. (Pe)
14.25 Pfizer, Inc.
14.26 Phase Genomics
14.27 Proderm IQ
14.28 Prodigest
14.29 Promega Corporation
14.30 PureFlora Inc.
14.31 QIAGEN
14.32 Quay Pharma
14.33 Whole Biome
14.34 Xycrobe Therapeutics, Inc.
14.35 Zymo Research

15 Key Microbiome Developments
15.1 Agreements, Partnerships, Collaborations and Joint Ventures
15.2 Acquisitions & Mergers
15.3 New Product Launch
15.4 Expansions
15.5 Other Key Strategies

For more information about this report visit https://www.researchandmarkets.com/research/jvqpbd/500_million?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biopharmaceuticals